Clinical trials
Recruiting trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,857 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 17 |
| 2015 | 20 |
| 2016 | 27 |
| 2017 | 34 |
| 2018 | 34 |
| 2019 | 58 |
| 2020 | 64 |
| 2021 | 140 |
| 2022 | 193 |
| 2023 | 320 |
| 2024 | 543 |
| 2025 | 804 |
| 2026 | 546 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 2,857 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 98 |
| Imperial College London | 90 |
| University College, London | 70 |
| Merck Sharp & Dohme LLC | 60 |
| University of Oxford | 55 |
| Queen Mary University of London | 48 |
| University of Edinburgh | 48 |
| Eli Lilly and Company | 45 |
| King's College London | 41 |
| University of Nottingham | 39 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 120 |
| Carcinoma, Non-Small-Cell Lung | 91 |
| Breast Neoplasms | 70 |
| Heart Failure | 70 |
| Prostatic Neoplasms | 69 |
| Obesity | 61 |
| Colorectal Neoplasms | 58 |
| Lung Neoplasms | 49 |
| Ovarian Neoplasms | 48 |
| Cardiovascular Diseases | 45 |
Trials
Showing 26 to 50 of 2,857. Each trial links to its page on Pharma Observatory.
2,757 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.